Skip to content
Review

Microenvironment-adaptive drug delivery systems for ulcerative colitis: from pathological constraints to rational design.

Aug 2026 · Expert Opinion on Drug Delivery · pp. 1-19 · 0 citations · 138 references
Medicine

TL;DR

A pathology-driven microenvironment-adaptive framework is proposed and the limitations of current delivery strategies are critically evaluated, followed by a discussion of how molecular building blocks and delivery platforms can be engineered to realize microenvironment-adaptive therapeutic strategies.

Abstract

INTRODUCTION Ulcerative colitis (UC) is characterized by recurrent, chronic, and nonspecific intestinal inflammation. It is strongly associated with an increased risk of colorectal cancer, representing a global public health challenge. However, the complex pathological microenvironment of UC, characterized by mucus barrier disruption, increased epithelial permeability, immune dysregulation, and oxidative stress, substantially compromises the therapeutic efficacy of conventional drugs. AREAS COVERED Nanomedicine delivery systems have offered new opportunities for UC treatment, these systems can optimize drug transport, distribution, and controlled release, thereby better addressing the therapeutic requirements of UC. Relevant literature was identified through PubMed, with a primary focus on studies published between January 2016 and August 2026. EXPERT OPINION The fundamental relationship between disease pathology and delivery system design remains insufficiently explored. To address this gap, this review proposes a pathology-driven microenvironment-adaptive framework and critically evaluates the limitations of current delivery strategies. We translate the key pathological barriers into actionable design criteria, followed by a discussion of how molecular building blocks and delivery platforms can be engineered to realize microenvironment-adaptive therapeutic strategies. This review provides insights and new perspectives for the rational design of microenvironment-adaptive systems for UC.

View source

Similar papers

Review Open access Sep 2026

From ROS-Responsive Nanosystems to Microbiome Modulation: Advanced Drug Delivery Reshaping Inflammatory Bowel Disease and Chronic Inflammatory Diseases

Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, serves as a compelling model for advanced drug delivery innovation owing to its well-characterised inflammatory microenvironment and significant unmet clinical need. This semi-systematic review evaluated three converging innovation s...

Saravanakumar Parameswaran, Satheesh Babu Natarajan, Nivetha Shanmugam et al. · 0 citations
Review Open access Oct 2026

Engineering Nanomaterial Platform for Inflammatory Bowel Disease: Three-Dimensional Integration of Delivery Mechanism, Therapeutic Drug Delivery and Intelligent Material Design

Abstract Inflammatory bowel disease (IBD) is a chronic intestinal inflammatory disorder with a complex etiology and a high recurrence rate. Conventional treatments face significant limitations in targeting, stability, and efficacy. Going beyond conventional reviews that focus on isolated mechanisms, this review offers...

Jun-Hui Qian, Si-Qi Shen, Si-Jia Chen et al. · 0 citations
Review Aug 2026

Polysaccharide-based colon targeting drug delivery systems: Overview on challenges, opportunities and prospects

Abstract Colon-targeted drug delivery systems (CTDDS) are a current focus in the medical field, as they directly target the colon, enabling better management of diseases such as ulcerative colitis (UC), Crohn’s disease (CD), inflammatory bowel disease (IBD), and colorectal cancer (CRC) with minimal side effects. This s...

Ekta Rathore, Nidhi Agrawal, Mohammad Akbar Siddiqui et al. · 0 citations
Open access Aug 2026

Reprogramming the gastrointestinal microenvironment with intelligent biomaterials and digital medicine: a perspective on precision intervention for digestive diseases

Digestive diseases, including inflammatory bowel disease (IBD), gastrointestinal mucosal injury, colorectal cancer-associated inflammation, peptic ulcer disease, and postoperative gastrointestinal complications, are increasingly understood as disorders of a dynamic and spatially heterogeneous microenvironment rather th...

Lin-Ying Peng, Xue-Yan Jia, Huan Chen et al. · 0 citations
Review Oct 2026

Recent advances in antioxidant nanozymes for the treatment of inflammatory bowel disease.

To overcome biopharmaceutical bottlenecks, an overview of nanozyme-based intelligent delivery platforms tailored for the inflamed gut are provided, covering endogenous/exogenous stimuli-responsive, biomimetic, and microbiota-mediated systems.

Zuo-Yi Shen, Shi-Qiao Rui, Jing-Qi Zhang et al. · 0 citations
Review Aug 2026

An Emerging Strategy for Skin Disease Treatment: Targeting the Skin Inflammatory Microenvironment with Responsive Drug Delivery Systems

The treatment of inflammatory skin diseases poses significant challenges due to the complex Inflammatory Microenvironment (IME) and inherent limitations of the skin barrier. However, given its dynamic nature and pivotal involvement in disease pathogenesis, the IME represents an ideal target for precision interventi...

Yang-Yang Zhang, Jun-Kun Qu, Yu-Ling Chen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.